Mats-Olof Wallin
Finanzdirektor/CFO bei OxThera AB
Aktive Positionen von Mats-Olof Wallin
| Unternehmen | Position | Beginn | Ende |
|---|---|---|---|
OxThera AB
 OxThera AB Pharmaceuticals: GenericHealth Technology OxThera AB develops pharmaceutical products for treatment of hyperoxaluria. Its intellectual property includes worldwide patents for compositions and treatment of hyperoxaluria with bacteria and enzymes. The firm?s products in pipeline include Oxabact, for the treatment of primary hyperoxaluria and oxazyme for the prevention of oxalate malabsorption and recurring kidney stones in secondary hyperoxaluria. The company was founded in 2005 and is headquartered in Stockholm, Sweden. | Finanzdirektor/CFO | 01.01.2020 | - |
Karriereverlauf von Mats-Olof Wallin
Ehemalige bekannte Positionen von Mats-Olof Wallin
| Unternehmen | Position | Beginn | Ende |
|---|---|---|---|
| KARO PHARMA AB (PUBL) | Finanzdirektor/CFO | 01.01.2018 | 01.10.2019 |
| SWEDISH ORPHAN BIOVITRUM AB | Finanzdirektor/CFO | 08.04.2013 | 20.07.2018 |
| BIOTAGE AB | Finanzdirektor/CFO | 17.05.2010 | 01.01.2012 |
| Public Communications Contact | 17.05.2010 | 01.01.2012 |
Ausbildung von Mats-Olof Wallin
| University of Uppsala | Undergraduate Degree |
Statistik
International
| Schweden | 6 |
Operativ
| Director of Finance/CFO | 4 |
| Public Communications Contact | 1 |
| Undergraduate Degree | 1 |
Sektoral
| Health Technology | 5 |
| Consumer Services | 2 |
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Unternehmensverbindungen
| Börsennotierte Unternehmen | 3 |
|---|---|
| BIOTAGE AB | Health Technology |
| SWEDISH ORPHAN BIOVITRUM AB | Health Technology |
| KARO PHARMA AB (PUBL) | Health Technology |
| Private Unternehmen | 1 |
|---|---|
OxThera AB
OxThera AB Pharmaceuticals: GenericHealth Technology OxThera AB develops pharmaceutical products for treatment of hyperoxaluria. Its intellectual property includes worldwide patents for compositions and treatment of hyperoxaluria with bacteria and enzymes. The firm?s products in pipeline include Oxabact, for the treatment of primary hyperoxaluria and oxazyme for the prevention of oxalate malabsorption and recurring kidney stones in secondary hyperoxaluria. The company was founded in 2005 and is headquartered in Stockholm, Sweden. | Health Technology |
- Börse
- Insiders
- Mats-Olof Wallin
- Erfahrung
